Telomerase-derived CD4 Th1-inducer cancer vaccine
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Telomerase-derived CD4 Th1-inducer cancer vaccine, covering 2026-03-16 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma [Phase 2]